Finding an “Achilles’ heel” of cancer: The role of glucose and glutamine metabolism in the survival of transformed cells
Author:
- 15 July 2008
- journal article
- research article
- Published by Taylor & Francis in Cell Cycle
- Vol. 7 (14) , 2083-2089
Abstract
Multiple lines of evidence indicate that the process of tumorigenesis is often associated with altered metabolism of two major nutrients, glucose and glutamine. These two nutrients are engaged in multiple metabolic pathways that can be required for cell viability. The roles of glucose and glutamine in the survival of transformed cells both in vitro and in vivo have been separately evaluated in various cell systems, and glucose as the major cellular energy source has received most of the attention. At the same time, data suggests that the inclusion of glucose and glutamine into specific metabolic pathways and cellular sensitivity to the availability of either of these nutrients depends on the cell origin and the combination and nature of transforming events. Exploiting cell metabolism to develop selective cancer therapeutics requires consideration of these factors and evaluation of the requirement of glucose and glutamine metabolism for survival of different transformed cells. Here we discuss possible molecular mechanisms underlying oncogene-induced sensitivity to deprivation of these nutrients.Keywords
This publication has 45 references indexed in Scilit:
- The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and ProliferationCell Metabolism, 2008
- TIGAR, a p53-Inducible Regulator of Glycolysis and ApoptosisCell, 2006
- AMP-Activated Protein Kinase Induces a p53-Dependent Metabolic CheckpointMolecular Cell, 2005
- Molecular mechanisms of glutamine actionJournal of Cellular Physiology, 2005
- Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylaseCancer Cell, 2005
- Beginnings of a signal-transduction pathway for bioenergetic control of cell survivalTrends in Biochemical Sciences, 2004
- Mitochondrial dysfunction in cancerMitochondrion, 2004
- A trip to the ER: coping with stressTrends in Cell Biology, 2004
- Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapiesCancer Treatment Reviews, 2003
- Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damageNature, 2002